What exactly did Cowen change in the SKIN analyst rating on March 16, 2026?

Cowen maintained SKIN at Hold on **March 16, 2026** and lowered its price target to **$1.50**, signaling reduced upside while keeping a neutral stance.

How should investors interpret the SKIN analyst rating and the lower price target?

A Hold with a lower PT means reduced expected upside. Investors should review financial catalysts and consider position sizing until clearer recovery signs emerge.

Does the SKIN analyst rating predict immediate stock movement?

Not necessarily. Cowen's note produced a modest **1.4% ($0.02)** price move in the feed, showing limited immediate impact. Long-term moves depend on fundamentals and liquidity.

How does Meyka AI view the SKIN analyst rating in its grading?

Meyka AI rates SKIN **B**, factoring in benchmark comparison, sector performance, growth metrics, and analyst consensus, which aligns with Cowen's cautious Hold.

Analyst Ratings

Cowen Keeps SKIN at Hold, Cuts PT to $1.50 Mar 16 2026 The Beauty Health Company

ByHuzaifa Zahoor March 17, 2026

Cowen kept The Beauty Health Company (SKIN) at Hold on March 16, 2026, while lowering its price target to $1.50. This SKIN analyst rating update signals continued caution from a notable sell-side firm. The move leaves investors with a mixed signal: Cowen is not tilting to Buy or Sell, but it trimmed valuation assumptions. Meyka AI’s platform flags the action as notable given recent trading and the company’s market cap of $152,366,156. The SKIN analyst rating change matters for short-term traders and long-term holders.